Drug Repurposing Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[228+ Pages Report] According to Facts & Factors, the global Drug Repurposing market size was estimated at USD 36.87 billion in 2025 and is expected to reach USD 59.30 billion by the end of 2034. The Drug Repurposing industry is anticipated to grow by a CAGR of 5.42% between 2026 and 2034. The Drug Repurposing Market is driven by the rising demand for cost-effective strategies to accelerate drug development by identifying new therapeutic uses for existing approved drugs, thereby significantly reducing development risks, timelines, and costs while improving patient outcomes across various disease areas.

Market Overview

Drug repurposing, also known as drug repositioning or drug re-profiling, refers to the systematic process of discovering and developing new therapeutic applications for existing drugs that have already been approved for other medical conditions or have undergone partial clinical development. This innovative approach capitalizes on the well-documented safety profiles, pharmacokinetic data, and manufacturing processes of established compounds, allowing pharmaceutical companies to bypass many of the lengthy and expensive early-stage discovery and preclinical phases typically associated with de novo drug development. By leveraging computational biology, artificial intelligence, high-throughput screening, and real-world evidence, researchers can identify novel disease targets and mechanisms of action that align with the pharmacological properties of these drugs, ultimately accelerating time-to-market and expanding treatment options for unmet medical needs.

This methodology not only mitigates the inherent risks of traditional drug discovery but also promotes sustainability within the pharmaceutical ecosystem by maximizing the value of intellectual property and existing drug libraries. It has emerged as a critical strategy in addressing complex and rare diseases where conventional development pathways prove economically unviable or too time-consuming.

Key Insights

• As per the analysis shared by our research analyst, the global Drug Repurposing market is expected to witness a significant growth rate of 5.42% CAGR during the forecast period of 2026-2034.
• In terms of revenue, the global Drug Repurposing market was valued at USD 36.87 billion in 2025 and is projected to reach USD 59.30 billion by the end of 2034.
• The market is driven by the rising demand for cost-effective strategies to accelerate drug development by finding new therapeutic uses for existing drugs, thereby reducing development risks and timelines while enhancing patient outcomes.
• Based on the therapeutic area segment, the oncology subsegment dominated the market with a 40% share as it benefits from the high global burden of cancer, the mechanistic versatility of many existing drugs that exhibit anti-tumor properties, and the urgent need for rapid therapeutic innovations in personalized oncology treatments that leverage established safety data.
• Based on the drug type segment, the small molecules subsegment dominated the market with a 60% share because small-molecule drugs offer superior oral bioavailability, ease of synthesis and formulation, extensive historical clinical data, and cost-effective scalability compared to larger biologics, making them ideal candidates for rapid repurposing across multiple indications.
• Based on the end user segment, the pharmaceutical and biotechnology companies subsegment dominated the market with a 57% share owing to their substantial in-house drug libraries, advanced R&D infrastructure, strong regulatory expertise, and strategic focus on extending product lifecycles through repurposing to offset patent cliffs and maximize ROI on existing assets.
• Based on the region segment, the North America region dominated the market with a 43% share due to its robust pharmaceutical ecosystem, supportive regulatory frameworks such as the FDA’s 505(b)(2) pathway, high investment in AI-driven discovery platforms, and concentration of leading biotech firms and research institutions that facilitate swift clinical translation and commercialization of repurposed therapies.

Growth Drivers

• Rising Prevalence of Chronic and Rare Diseases

The increasing global incidence of chronic conditions such as cancer, neurodegenerative disorders, and metabolic syndromes, coupled with the growing burden of rare and orphan diseases, has created an urgent need for innovative yet accessible treatment solutions that can be developed quickly and affordably. Drug repurposing addresses this demand by utilizing compounds with established safety and efficacy profiles, thereby shortening the typical 10-15 year drug development timeline to as little as 3-5 years and significantly lowering associated costs, which encourages broader adoption among healthcare providers and payers seeking sustainable therapeutic options.

• Advancements in AI and Computational Technologies

Integration of artificial intelligence, machine learning algorithms, and big data analytics has revolutionized the identification of new drug-disease associations by analyzing vast datasets on molecular interactions, gene expression, and clinical outcomes at unprecedented speeds. These technological breakthroughs enable precise prediction of repurposing opportunities, reduce failure rates in clinical trials, and foster collaborative ecosystems between academia and industry, ultimately driving higher success rates and attracting substantial venture capital into repurposing-focused biotech ventures.

Restraints

• Intellectual Property and Patent Protection Challenges

Complex intellectual property landscapes surrounding off-patent drugs and limited exclusivity periods for repurposed indications often deter pharmaceutical companies from investing heavily in repurposing programs, as they struggle to secure adequate returns on investment amid generic competition. Regulatory uncertainties regarding data exclusivity and the potential for litigation over repurposed uses further complicate commercialization efforts, leading to hesitation among key stakeholders and slowing overall market momentum despite the scientific promise of the approach.

• Limited Financial Incentives for Off-Patent Drugs

Many repurposed candidates are older generic molecules that lack strong market exclusivity incentives, resulting in insufficient funding for large-scale clinical validation studies and reduced motivation for big pharma to prioritize such projects over novel blockbuster candidates. This financial disincentive creates a gap in the development pipeline for repurposed therapies targeting smaller patient populations or neglected diseases, constraining the market’s ability to fully realize its potential in addressing global health inequities.

Opportunities

• Expansion into Rare and Neglected Diseases

The repurposing framework presents significant opportunities to tackle rare and neglected tropical diseases where traditional drug development is economically unfeasible, supported by orphan drug designations and government incentives that provide tax credits, market exclusivity extensions, and accelerated approval pathways. By repurposing existing compounds for these indications, companies can achieve faster market entry, lower development risks, and contribute to global health initiatives while building diversified portfolios that enhance long-term revenue stability.

• Strategic Collaborations and AI-Driven Platforms

Growing partnerships between pharmaceutical giants, AI technology providers, and academic institutions are opening new avenues for high-throughput screening and data-sharing platforms that accelerate repurposing discoveries and de-risk investment decisions. These collaborations facilitate open innovation models, shared risk-reward structures, and access to proprietary datasets, positioning early adopters to capture substantial market share through first-mover advantages in emerging therapeutic areas.

Challenges

• Regulatory and Safety Hurdles

Navigating evolving regulatory requirements for repurposed drugs, including the need for new clinical data specific to novel indications despite existing safety profiles, poses significant compliance challenges that can delay approvals and increase development costs. Post-marketing surveillance requirements and potential unforeseen side effects in new patient populations further complicate risk management, requiring robust pharmacovigilance strategies that strain resources for smaller biotech players.

• Data Integration and Validation Issues

Integrating heterogeneous datasets from disparate sources while ensuring data quality, reproducibility, and ethical considerations remains a persistent technical challenge that can lead to false positives in repurposing predictions and subsequent clinical failures. Overcoming these issues demands sophisticated bioinformatics infrastructure and interdisciplinary expertise, which not all market participants possess, thereby limiting the scalability of repurposing initiatives across the industry.

Report Scope

Report Attribute	Details
Market Size 2025	USD 36.87 Billion
Projected Market Size in 2034	USD 59.30 Billion
CAGR Growth Rate	5.42% CAGR
Base Year	2025
Forecast Years	2026-2034
Key Market Players	Pfizer Inc., Novartis AG, Eli Lilly and Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Recursion Pharmaceuticals Inc., Amgen Inc., and Others.
Key Segment	By Therapeutic Area, By Drug Type, By End User, and By Region
Major Regions Covered	North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Purchase Options	Request customized purchase options to meet your research needs. Explore purchase options

Market Segmentation

The Drug Repurposing market is segmented by therapeutic area, drug type, end-user, and region.

Based on therapeutic area segment, the Drug Repurposing market is divided into Oncology, Neurology and CNS Disorders, Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, and Others. The most dominant segment is Oncology, which leads due to the high prevalence of cancer worldwide, the ability of many approved drugs to target multiple oncogenic pathways through polypharmacology, and the pressing need for rapid, cost-effective therapies that can be combined with existing immunotherapies or targeted agents to improve survival rates and quality of life; this dominance drives overall market growth by attracting the largest share of R&D investments and facilitating quicker regulatory approvals via expedited pathways for oncology indications. The second most dominant is Neurology and CNS Disorders, which benefits from the mechanistic overlap between existing psychiatric and neurodegenerative drugs and emerging disease biology, helping to address the growing elderly population and unmet needs in conditions like Alzheimer’s and Parkinson’s by repurposing compounds with proven blood-brain barrier penetration.

Based on drug type segment, the Drug Repurposing market is divided into Small Molecules, Biologics, and Others. The most dominant segment is Small Molecules, which prevails because of their favorable pharmacokinetic properties, ease of chemical modification, established large-scale manufacturing processes, and extensive historical clinical safety data that enable faster repurposing cycles and lower production costs compared to biologics; this dominance propels market expansion by allowing pharmaceutical companies to efficiently screen vast compound libraries and bring repurposed candidates to market with minimal additional formulation challenges. The second most dominant is Biologics, which is gaining traction through advances in protein engineering and monoclonal antibody technologies that unlock new indications for complex macromolecules previously limited to specific therapies.

Based on end-user segment, the Drug Repurposing market is divided into Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals and Clinics, and Others. The most dominant segment is Pharmaceutical and Biotechnology Companies, which leads as they possess proprietary drug libraries, deep domain expertise in clinical development, and strong financial resources to fund large repurposing programs while leveraging repurposing to extend patent lifecycles and mitigate revenue losses from generics; this dominance accelerates market growth by enabling vertical integration of discovery through commercialization and fostering strategic alliances with technology providers. The second most dominant is Contract Research Organizations, which support smaller biotechs and academia by providing specialized screening, bioinformatics, and clinical trial services that reduce internal infrastructure costs.

Recent Developments

• In early 2026, Recursion Pharmaceuticals announced a major collaboration with a leading AI platform provider to screen over 100,000 compounds for new repurposing candidates targeting rare genetic disorders, resulting in three advanced preclinical programs entering IND-enabling studies within months.
• In late 2025, Novartis AG secured FDA approval for the repurposing of an established cardiovascular drug for a novel metabolic indication, marking one of the fastest 505(b)(2) pathways completed and expanding its oncology-adjacent portfolio through synergistic mechanisms.
• In mid-2025, Eli Lilly and Company partnered with an academic consortium to leverage real-world evidence databases for repurposing anti-inflammatory agents in neurodegenerative conditions, accelerating Phase II trials and demonstrating reduced cognitive decline in early patient cohorts.
• In 2026, Teva Pharmaceutical Industries Ltd. expanded its repurposing pipeline by acquiring rights to a discontinued small-molecule candidate, utilizing AI-driven target identification to fast-track it for infectious disease applications in emerging markets.

Regional Analysis

• North America to dominate the global market

North America maintains its leading position through a highly developed pharmaceutical and biotechnology ecosystem centered in the United States, where major hubs like Boston, San Francisco, and Research Triangle Park host world-class research institutions, venture capital firms, and regulatory bodies that actively promote repurposing via streamlined approval pathways such as the FDA’s 505(b)(2) process. The region’s dominance is further reinforced by substantial government funding for precision medicine initiatives, widespread adoption of AI and big data analytics in drug discovery, and strong collaborations between academia and industry that facilitate rapid translation of repurposed candidates into clinical practice. Canada contributes significantly through its robust life sciences sector and supportive orphan drug policies, enabling smaller biotechs to thrive alongside global giants. Overall, the concentration of intellectual property expertise, advanced healthcare infrastructure, and high patient awareness drives continuous innovation and market leadership in repurposing strategies tailored to chronic and rare diseases prevalent in aging populations.

Europe follows closely as a mature market characterized by strong regulatory harmonization under the European Medicines Agency and a focus on cost-containment measures that favor repurposed drugs for public health systems. Countries like Germany, the United Kingdom, and Switzerland lead with their advanced research clusters, such as the BioNTech and Roche ecosystems in oncology repurposing, while France and Italy emphasize infectious disease and cardiovascular applications through national health programs. The region benefits from collaborative EU-funded projects that integrate real-world evidence and AI platforms, fostering cross-border partnerships that accelerate repurposing for neglected diseases. Academic centers in Scandinavia and the Benelux countries provide deep expertise in bioinformatics, supporting the identification of new indications for off-patent molecules and ensuring high-quality clinical validation. This environment promotes sustainable growth by balancing innovation incentives with pricing pressures in universal healthcare systems.

Asia Pacific is emerging as the fastest-growing region, propelled by rapid healthcare infrastructure expansion, increasing R&D investments from local and multinational players, and government initiatives in countries like China, India, and Japan aimed at reducing drug development costs through repurposing. China dominates with its vast patient population, state-backed AI drug discovery programs, and focus on oncology and infectious diseases, while India leverages its generic manufacturing prowess and clinical trial expertise to position itself as a global repurposing hub. Japan contributes through its aging demographic and emphasis on neurodegenerative repurposing, supported by advanced regulatory reforms. Southeast Asian nations are adopting the approach for tropical diseases, benefiting from technology transfers and cost advantages that attract outsourcing from Western firms. Collectively, these dynamics create a vibrant ecosystem that bridges traditional medicine knowledge with modern computational tools.

Latin America exhibits steady progress driven by rising healthcare awareness and efforts to address neglected tropical diseases through repurposing initiatives in Brazil and Mexico, where academic and public-private partnerships are gaining traction. The region’s growth is supported by improving regulatory frameworks and increasing foreign investment in clinical research, though challenges in infrastructure persist in smaller economies.

The Middle East and Africa show promising potential, particularly in the Gulf countries where sovereign wealth funds are investing in biotech innovation hubs focused on repurposing for metabolic and cardiovascular conditions prevalent in the region. Africa’s focus remains on infectious disease repurposing through international collaborations, laying the foundation for future market expansion despite current resource constraints.

Competitive Analysis

The global Drug Repurposing market is dominated by players:

• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Roche Holding AG
• Teva Pharmaceutical Industries Ltd.
• Recursion Pharmaceuticals Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Sanofi S.A.
• GSK plc
• and Others.

The global Drug Repurposing market is segmented as follows:

By Therapeutic Area

• Oncology
• Neurology and CNS Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Disorders
• Others

By Drug Type

• Small Molecules
• Biologics

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Hospitals and Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America